

CellaVision® launches a complete workflow solution for low-volume hematology laboratories

On July 27, 2022, CellaVision® announces the launch of DIFF-Line™ by CellaVision, a new workflow solution for low-volume hematology laboratories, at the AACC convention in Chicago.

DIFF-Line™ by CellaVision consists of three instruments for smearing, staining, and analyzing peripheral blood smears: CellaVision® DC-1, RAL® SmearBox, and RAL® StainBox.

- **CellaVision® DC-1** is a single-slide analyzer that automates and digitizes the process of analyzing peripheral blood smears. The analyzer has an automated microscope, a high-quality digital camera, and an advanced computer system that uses artificial intelligence to locate, digitally capture, and pre-classify cells from stained blood smears. The pre-classified cells are presented on a computer screen for review and verification. The CellaVision® DC-1 was launched in 2019 and received FDA clearance in October 2020.
- **RAL® SmearBox** produces high-quality peripheral blood smears. The automated instrument uses a patented consumable to produce smears directly from a closed whole sample tube. CellaVision is introducing the RAL SmearBox to the market today July 27, 2022.
- **RAL® StainBox** stains blood smears consistently and by laboratory guidelines. The semi-automated instrument utilizes the bath method and guides the laboratory through a step-by-step staining process. Improved staining protocols contribute to ease of use and optimized DC-1 performance. The RAL® StainBox uses MCDh methanol-free stains to ensure high stain quality and reproducibility while reducing staff exposure to toxic chemicals.

Simon Ostergaard, CellaVision CEO, comments on the launch: "DIFF-Line™ by CellaVision is a comprehensive solution for small labs that want to improve diagnostic certainty. With the acquisition of RAL Diagnostics, CellaVision can now offer a complete workflow for smearing, staining, and analyzing peripheral blood smears in hematology labs that handle a smaller amount of daily blood samples."

DIFF-Line™ by CellaVision is available on the European market from July 2022 and will be rolled out in more markets in 2022. All CellaVision products are sold through their distribution partners.

[ENDS]

PRESS CONTACTS

Peter Wilson

VP Global Marketing, CellaVision

Peter.wilson@cellavision.com

+46 709 92 24 54

Andrew Gill

Director Marketing, CellaVision

andrew.gill@cellavision.com

+46 733 16 94 97

LINKS:

- www.cellavision.com/diffline
- [DIFF-Line™ by CellaVision video on Youtube](#)

Contact

Andrew Gill

Director Marketing

Direct: +46 733 169 497

Web: www.cellavision.com

Email: Andrew.Gill@cellavision.se

About Us

CellaVision is an innovative, global medical technology company that develops and sells its own leading systems for routine analysis of blood and other body fluids in health care services. The products replace manual laboratory work, and secure and support effective workflows and skills development within and between hospitals. The company has leading-edge expertise in sample preparation, image analysis, artificial intelligence and automated microscopy. Sales are via global partners with support from the parent company in Lund and by the company's 17 local market support organizations covering more than 40 countries. In 2021, sales were SEK 566 million and the company's growth target is 15% per year over an economic cycle. CellaVision's registered office is in Lund, Sweden. The share is listed on the Nasdaq Stockholm, Mid Cap list. Read more at www.cellavision.com

Image Attachments

[DIFF Line By CellaVision](#)

Attachments

[CellaVision® launches a complete workflow solution for low-volume hematology laboratories](#)